Industry Overview

Anal and colorectal cancer market was valued at $13.6 billion in 2025 and is projected to reach $20.5 billion by 2035, growing at a CAGR of 4.3% during the forecast Period (2026-2035). The gmarket is driven by factors like an aging population, rising cancer incidence, and increasing awareness about early detection and screening. Key market drivers include advancements in diagnostic technologies, the development of novel therapeutics such as targeted therapies and immunotherapies, and government initiatives for affordable treatment and screening.

Market Dynamics

Rising Global Incidence and Growing Screening Adoption

One of the strongest drivers of the global anal and colorectal cancer market is the rising prevalence of the disease worldwide. Increasing life expectancy, aging populations, sedentary lifestyles, unhealthy diets, obesity, and smoking collectively contribute to a consistent rise in colorectal cancer incidence across both developed and emerging economies. Governments and healthcare systems are strengthening screening programs such as FIT/FOBT testing, colonoscopies, and early detection initiatives. As screening becomes more accessible and mandatory in several countries, more cases are detected at earlier stages, increasing the demand for diagnostic systems, biopsy tools, endoscopic platforms, and subsequent therapeutic procedures. This surge in early identification significantly expands the overall market volume for both diagnostics and treatment modalities.

Advancements in Diagnostics, Therapeutics, and Precision Oncology

Technological innovation is another key driver accelerating market growth. Improved imaging solutions (AI-powered colonoscopy, high-resolution endoscopy, capsule endoscopy), molecular tests, ctDNA liquid biopsies, and genetic profiling tools are transforming the diagnostic landscape by enabling early and accurate tumor detection. On the treatment side, targeted therapies, immunotherapies (PD-1/PD-L1 inhibitors), monoclonal antibodies, combination regimens, and personalized treatment pathways are becoming central to clinical practice. These innovations increase treatment effectiveness, extend patient survival rates, and raise per-patient healthcare spending. The strong shift toward precision oncology where treatment is tailored to molecular and genetic tumor characteristics continues to expand demand for companion diagnostics and novel drug development, driving collaboration between pharmaceutical companies, diagnostic manufacturers, and research institutes.

Expanding Healthcare Infrastructure, Reimbursement Support, and Access to Advanced Care

Favorable reimbursement policies, rising healthcare expenditure, and expanding oncology infrastructure in developing markets are significantly boosting demand for anal and colorectal cancer solutions. In regions like North America and Western Europe, comprehensive insurance coverage for screening, endoscopy procedures, and advanced therapies encourages higher utilization of diagnostic and treatment services. Meanwhile, emerging economies in Asia-Pacific, Latin America, and the Middle East are investing heavily in cancer-care centers, early-diagnosis programs, and public awareness campaigns. These developments increase access to advanced therapeutics, minimally invasive surgical techniques, and radiotherapy systems. Additionally, government-led cancer prevention strategies, value-based care models, and funding for early detection programs further strengthen market penetration, making improved access and reimbursement a major catalyst for global market expansion.

Market Segmentation

• Based on the treatment type, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.
• Based on the end user, the market is segmented into hospitals, ambulatory surgery centers, and cancer research centers.

Surgery Segment to Grow at a Considerable Market Share

Surgery remains the largest treatment segment and holds the dominant share of the Global Anal and Colorectal Cancer Market. Colorectal cancer is primarily diagnosed at stages where resection of the tumor remains the gold standard, and surgical intervention is recommended in nearly all localized and many regionally advanced cases. Surgical procedures such as colectomy, proctectomy, minimally invasive laparoscopic surgery, and robotic-assisted colorectal surgeries are widely adopted due to their high success rate, curative intent, and ability to significantly improve long-term survival. Surgery is typically the first-line treatment for early-stage cancer and is also integral to multimodal treatment approaches alongside chemotherapy and radiation therapy.

Hospitals: A Key Segment in Market Growth

The hospital segment is the key end-user driving growth in the global anal and colorectal cancer market due to its ability to provide comprehensive cancer care, including screening, diagnostics, surgical interventions, chemotherapy, radiotherapy, and post-treatment follow-up, all under one roof. Hospitals serve as primary hubs for national screening programs, performing colonoscopies, FIT/FOBT tests, and advanced endoscopic procedures that require specialized equipment and trained personnel, which smaller ambulatory centers or research facilities cannot fully accommodate. The increasing global incidence of colorectal cancer, coupled with rising awareness of early detection, has expanded patient volumes in hospitals, boosting demand for diagnostics and therapeutic services.

Additionally, hospitals are at the forefront of adopting technological advancements such as AI-assisted imaging, molecular diagnostics, liquid biopsies, and precision oncology treatments, enabling personalized therapies and higher per-patient spending. Geographically, hospitals dominate in North America and Europe due to robust healthcare infrastructure and favorable reimbursement, while emerging markets in Asia-Pacific and Latin America are witnessing rapid growth as government investments expand hospital-based oncology services. Overall, the hospital segment’s capacity to deliver end-to-end care, integrate advanced technologies, and support large-scale screening initiatives positions it as the fastest-growing and highest-revenue end-user segment in the anal and colorectal cancer market.

Regional Outlook

The global anal and colorectal cancer market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

North America is the dominant region in the global anal and colorectal cancer market. The US dominates the global anal and colorectal cancer market, holding the largest share due to a combination of high disease prevalence, advanced healthcare infrastructure, and widespread adoption of screening and treatment technologies. The country has well-established colorectal cancer screening programs, including colonoscopies, stool-based tests, and non-invasive molecular diagnostics, which enable early detection and improved patient outcomes. A strong emphasis on precision medicine, including targeted therapies, immunotherapies, and companion diagnostics, further drives market growth by increasing per-patient healthcare expenditure. The presence of leading diagnostic and pharmaceutical companies, such as Roche, Abbott, Guardant Health, Amgen, Merck, and Pfizer, also contributes to innovation, rapid technology adoption, and competitive development of novel therapeutics and diagnostic platforms.

In addition, favorable reimbursement policies, high insurance coverage, and a well-developed hospital and oncology care network ensure that patients have timely access to advanced treatments and diagnostic solutions. Research and development initiatives, supported by government funding and private investments, continue to enhance early detection methods and treatment protocols, reinforcing the country’s leadership position. North America’s market, led by the United States, is expected to maintain its dominance over the forecast period, driven by sustained technological innovation, comprehensive screening initiatives, and increasing awareness of colorectal cancer prevention and treatment strategies.Top of Form

Market Players Outlook

The major companies operating in the global anal and colorectal cancer market include Amgen Inc., Bristol Myers Squibb Co., Eli Lilly and Co., Hoffmann-La Roche Ltd., Merck & Co. Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In December 2024, Jemperli (dostarlimab) received Breakthrough Therapy Designation from the US FDA for treating locally advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) rectal cancer. This designation expedites the development of promising treatments, with dostarlimab previously granted Fast Track designation in January 2023. Clinical evidence shows a 100% clinical complete response in 42 patients treated with dostarlimab, with sustained responses observed over a median follow-up of 26.3 months. The ongoing AZUR-1 trial continues to evaluate its efficacy and safety. Current treatments for dMMR/MSI-H locally advanced rectal cancer typically involve chemotherapy, radiation, and surgery, which can negatively impact long-term quality of life. Dostarlimab is not yet approved for frontline treatment in this indication.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global anal and colorectal cancer market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.